Sacituzumab Tirumotecan Across Gynecologic Malignancies - Review - Therapeutic potential and recent evidence

Sep 22, 2026

Upload by Aran

Sacituzumab Tirumotecan is reviewed as a novel antibody-drug conjugate targeting TROP2 glycoprotein, which is highly expressed across malignant cells. The review summarizes early and emerging clinical activity in breast and lung cancer and focuses on ongoing evaluation for gynecologic malignancies. It compiles recent phase III trial information for cervical, ovarian, and endometrial cancers, including safety observations such as manageable toxicity and common adverse events. It also outlines the anticipated role of mature efficacy data and biomarker analyses.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Purpose of Review

Recent Findings

Summary

Highlights

Keywords

Introduction

Burden of gynecologic cancers and outcomes

Current Oncology Reports (2026) 28:69 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1912-026-01806-2 REVIEW SacituzumabTirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases Amalia A. Sofianidi1 · Evangelia Panagodimou2 · Emmanouil Kalampokas2 · Ioannis Georgakopoulos3 · Flora Zagouri1 Received: 9 April 2026 / Accepted: 11 June 2026 © The Author(s) 2026 Abstract Purpose of Review Sacizuzumab Tirumotecan is a novel antibody-drug conjugate targeting TROP2 glycoprotein, which is highly expressed across malignant cells. Sacizuzumab Tirumotecan has already demonstrated promising clinical activity in combating breast and lung cancer, and it is currently under evaluation for use against gynecologic malignancies. This review aims to highlight the therapeutic potential of Sacituzumab Govitecan in gynecologic malignancies and to summarize the most recent evidence supporting its clinical application. Recent Findings Ongoing phase III trials of Sacituzumab Tirumotecan include cervical, ovarian, and endometrial cancers. Preliminary safety data of Sacituzumab Tirumotecan indicates a manageable toxicity profile, with the most commonly reported adverse events including hematologic toxicity, oral mucositis, and alopecia. Summary Mature data from Phase III trials are anticipated to clarify the impact of Sacituzumab Tirumotecan on overall survival, progression-free survival, and objective response rates. Additionally, biomarker analyses may enhance patientselection strategies and refine prognostic assessment in gynecologic oncology. Highlights ● Antibody-drug conjugates (ADCs) are an advent in the management of oncology patients. ● Sacituzumab Tirumotecan (sac-TMT/MK-2870/SKB264) is a promising new ADC undergoing clinical trials in solid tumors. ● Promising results have been published with the use of Sacituzumab Tirumotecan in gynecologic malignancies, mainly cervical, ovarian and endometrial cancers. ● More mature data from phase III trials are expected soon. Keywords Sacituzumab tirumotecan · Sac-TMT · MK-2870 · Cervical · Ovarian · Endometrial · Antibody drug conjugates 􀀍 Amalia A. Sofianidi [amaliasof@med.uoa.gr](amaliasof@med.uoa.gr)[ ](amaliasof@med.uoa.gr)Evangelia Panagodimou [evapanagod@icloud.com](evapanagod@icloud.com)[ ](evapanagod@icloud.com)Emmanouil Kalampokas[m.kalampokas@gmail.com](m.kalampokas@gmail.com)[ ](m.kalampokas@gmail.com)Ioannis Georgakopoulos [ioangeo@med.uoa.gr](ioangeo@med.uoa.gr) Flora Zagouri [florazagouri@yahoo.co.uk](florazagouri@yahoo.co.uk) 1 Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine, Vasilissis Sofias 76, Athens 115 28, Greece 2 Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece 3 Radiation Oncology Unit, First Department of Radiology, Medical School, Aretaieion Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece Introduction Gynecological cancers pose a significant global health burden, with increasing trends in the past few years [1, 2] . Cervical, ovarian, and endometrial cancers are the most frequently diagnosed gynecological malignancies and constitute more than one-third of the newly diagnosed cancers globally in females. A total of 1,473,427 women were diagnosed with gynecological cancer in 2022, with 44.95% of these cases being identified as cervical cancer [2, 3]. Indeed, cervical cancer ranks highly regarding incidence and mortality, with a 5-year survival rate of 67% across all stages of the disease [4] . Patients diagnosed with ovarian cancer have an even worse prognosis, with 51% of patients remaining alive 5 years after diagnosis [5] . Endometrial cancer appears to have the most favorable prognosis of all, with a 5-year survival rate of 84% when all stages ofthe disease are combined [6] . However, outcomes remain particularly

FAQs

Sacituzumab Tirumotecan targets which molecule, and why is it relevant to gynecologic malignancies?

It targets the TROP2 glycoprotein, which is highly expressed across malignant cells. The review positions this as a valuable candidate for treating gynecologic cancers.

Which gynecologic cancer types are covered in the ongoing phase III trials mentioned in the review?

Ongoing phase III trials include cervical, ovarian, and endometrial cancers.

What adverse events and toxicity profile are reported as preliminary findings?

Preliminary safety data indicate a manageable toxicity profile, with commonly reported adverse events including hematologic toxicity, oral mucositis, and alopecia.

Sep 22, 2026

Upload by Aran